Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 October 2023 | Story Nonsindiso Qwabe | Photo Nonsindiso Qwabe
Mokitlane Manyarela
Mokitlane Manyarela reflects on his 41-year journey with the UFS Qwaqwa Campus

He has seen the many changing faces of the Qwaqwa Campus, and four decades later, Mokitlane Manyarela says he would not have it any other way.

Fondly known on campus as ‘Ntate Manyarela’, he has been with the campus for 41 years, having started on 1 January 1982 at the ripe age of 18 years. Manyarela recently received a long-service award for 36 years of service, dating back to when the campus moved to its current location from where it started at Lere la Tshepe in 1982.

He recalls arriving at the campus offices in town in 1982 seeking employment, as there were no “buildings or campus” back then.

“I started working as a general worker because there was nothing else to do. All the university’s content would come from Turfloop in those days. As time went by, I worked in the reprographic section, printing exam papers. That was my first official job until the campus moved in 1988 to where we’re now located. All the buildings that are now filling this campus were constructed right in front of my eyes,” he said.

He went on to work for various departments on the campus, such as procurement, cashiers, and finance. In 2007, he joined the transport department, and that is where he is still working as an assistant officer. “What’s made me stay this long is not getting into fights with anyone and always following instructions given to me. I’ve worked under many different bosses, and I believe that none of them have anything negative to say about me. Therefore, I can say I’ve never had a reason to leave because everything I’ve done, I have done wholeheartedly.”

Manyarela said the university also afforded his wife and children the opportunity to obtain their degrees, which is something he considers a huge achievement. “All that I have has been achieved at this institution. It’s been a wonderful journey. I have no complaints, and I am content. I’ve reached my old age here. I don’t know any other job or work environment; this place has become like home to me, and I’m prepared to still give my all to this university, even though old age is now catching up with me.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept